Recently, Chen and colleagues demonstrated that ANGPTL1 inhibits sorafenib resistance and cancer stemness in HCC cells preventing MET with a mechanism similar to lung cancer, proposing, thus, ANGPTL1 as a novel MET receptor inhibitor for advanced HCC therapy [16]. The gene discussed is MET; the disease is hepatocellular carcinoma.